Table 1.
Summary of the study population.
| Placebo (n = 8) | Ranolazine (n = 14) | P value | |
|---|---|---|---|
| Demographics | |||
| Age (years) | 53.6 ± 14.07 (22.0–68.0) | 55.4 ± 16.93 (24.0–78.0) | 0.809 |
| Female sex | 5 (62.5%) | 8 (57.1) | >.999 |
| White race | 6 (75.0) | 9 (64.3) | >.999 |
| 6-Minute walk distance (m) | 385.6 ± 179.8 (85.3–547.0) | 302.3 ± 113.7 (140.2–477.0) | 0.1954 |
| NT-proBNP (pg/ml) | 1,644.6 ± 928.9 (202.0–2,979.0) | 946.7 ± 933.7 (51.0–2,620.0) | 0.1066 |
| Creatinine (mg/dl) | 0.91 ± 0.36 (0.20–1.49) | 1.09 ± 0.35 (0.52–1.71) | 0.2698 |
| Clinical diagnosis | |||
| CTEPH | 0 | 2 (14.3) | |
| Congenital heart disease related PH | 1 (12.5) | 0 | |
| Connective tissue disease related PH | 1 (12.5) | 2 (14.3) | |
| Hereditary PAH | 1 (12.5) | 0 | |
| Idiopathic PAH | 5 (62.5) | 9 (64.3) | |
| PH with COPD | 0 | 1 (7.1) | 0.627 |
| NYHA functional class | |||
| II | 5 (62.5) | 6 (42.9) | |
| III | 2 (25) | 6 (42.9) | |
| IV | 1 (12.5) | 2 (14.3) | 0.8266 |
| PAH medication | |||
| Prostanoid | 6 (75) | 7 (50) | 0.3802 |
| Phosphodiesterase type 5 inhibitor | 6 (75) | 13 (92.9) | 0.2545 |
| sGC stimulator (Riociguat) | 1 (12.5) | 1 (7.14) | 0.4848 |
| Endothelin receptor antagonist | 7 (87.5) | 8 (57.1) | 0.1932 |
CTEPH, chronic thromboembolic pulmonary hypertension; COPD, chronic obstructive pulmonary disease; PAH, pulmonary arterial hypertension; NYHA, New York Heart Association; sGC, soluble guanylate cyclase.